"P(1A8243), S" . . "RIV/00216208:11120/07:00001457!RIV09-MSM-11120___" . . . . "Muhl\u0161teinov\u00E1, Z." . "3"^^ . "Quantitative determinination of circulating melanoma cells to early detection of disorder progression"@en . . "Detekce melanomov\u00FDch bun\u011Bk z perifern\u00ED krve je slibnou metodou k monitoringu diseminace n\u00E1dorov\u00FDch bun\u011Bk krevn\u00ED cestou a tedy k v\u010Dasn\u00E9mu rozpozn\u00E1n\u00ED metast\u00E1z. V dostupn\u00FDch publikac\u00EDch nen\u00ED jednotn\u00FD n\u00E1zor na klinickou relevanci t\u00E9to metody. V t\u00E9to pr\u00E1ci je popisov\u00E1na multimarkerov\u00E1 real-time RTPCR, kterou auto\u0159i pro tyto \u00FA\u010Dely \u00FAsp\u011B\u0161n\u011B etablovali. Kvantitativn\u011B bylo z perifern\u00ED krve stanoveno 5 marker\u016F melanomov\u00FDch bun\u011Bk: Melan-A/MART-1, gp 100, MAGE-3, MIA a tyrozin\u00E1za. V t\u00E9to prospek-tivn\u00ED studii byl proveden screening 65 pacient\u016F po resekci rizikov\u00E9ho ko\u017En\u00EDho melanomu. Krevn\u00ED odb\u011Bry od pacient\u016F k pr\u016Fkazu cirkuluj\u00EDc\u00EDch bun\u011Bk a stagingov\u00E1 vy\u0161et\u0159en\u00ED byla prov\u00E1d\u011Bna ka\u017Ed\u00E9 3 m\u011Bs\u00EDce po dobu 15 m\u011Bs\u00EDc\u016F. B\u011Bhem studie do\u0161lo k progresi u 18 pacient\u016F. U v\u0161ech t\u011Bchto pacient\u016F byla zaznamen\u00E1na statisticky signifikantn\u00ED elevace n\u00E1dorov\u00FDch marker\u016F v obdob\u00ED od 0 do 9 m\u011Bs\u00EDc\u016F od progrese onemocn\u011Bn\u00ED. Nejcitliv\u011Bj\u0161\u00EDm markerem progrese byl MAGE-3. U nemocn\u00FDch s progreduj\u00EDc\u00ED chorobou se nej\u010Dast\u011Bji na\u0161ly sou\u010Das\u011B pozitivn\u00ED 3 ma"@cs . "[5EC844317431]" . . "K\u0159emen, J." . "430279" . "Quantitative determinination of circulating melanoma cells to early detection of disorder progression"@en . "Lippert, J." . "8"^^ . "Detekce melanomov\u00FDch bun\u011Bk z perifern\u00ED krve je slibnou metodou k monitoringu diseminace n\u00E1dorov\u00FDch bun\u011Bk krevn\u00ED cestou a tedy k v\u010Dasn\u00E9mu rozpozn\u00E1n\u00ED metast\u00E1z. V dostupn\u00FDch publikac\u00EDch nen\u00ED jednotn\u00FD n\u00E1zor na klinickou relevanci t\u00E9to metody. V t\u00E9to pr\u00E1ci je popisov\u00E1na multimarkerov\u00E1 real-time RTPCR, kterou auto\u0159i pro tyto \u00FA\u010Dely \u00FAsp\u011B\u0161n\u011B etablovali. Kvantitativn\u011B bylo z perifern\u00ED krve stanoveno 5 marker\u016F melanomov\u00FDch bun\u011Bk: Melan-A/MART-1, gp 100, MAGE-3, MIA a tyrozin\u00E1za. V t\u00E9to prospek-tivn\u00ED studii byl proveden screening 65 pacient\u016F po resekci rizikov\u00E9ho ko\u017En\u00EDho melanomu. Krevn\u00ED odb\u011Bry od pacient\u016F k pr\u016Fkazu cirkuluj\u00EDc\u00EDch bun\u011Bk a stagingov\u00E1 vy\u0161et\u0159en\u00ED byla prov\u00E1d\u011Bna ka\u017Ed\u00E9 3 m\u011Bs\u00EDce po dobu 15 m\u011Bs\u00EDc\u016F. B\u011Bhem studie do\u0161lo k progresi u 18 pacient\u016F. U v\u0161ech t\u011Bchto pacient\u016F byla zaznamen\u00E1na statisticky signifikantn\u00ED elevace n\u00E1dorov\u00FDch marker\u016F v obdob\u00ED od 0 do 9 m\u011Bs\u00EDc\u016F od progrese onemocn\u011Bn\u00ED. Nejcitliv\u011Bj\u0161\u00EDm markerem progrese byl MAGE-3. U nemocn\u00FDch s progreduj\u00EDc\u00ED chorobou se nej\u010Dast\u011Bji na\u0161ly sou\u010Das\u011B pozitivn\u00ED 3 ma" . "11120" . "Gkalpakiotis, Spyridon" . . "Kvantitativn\u00ED stanoven\u00ED cirkuluj\u00EDc\u00EDch melanomov\u00FDch bun\u011Bk k v\u010Dasn\u00E9 detekci progrese onemocn\u011Bn\u00ED" . . "St\u0159\u00EDbrn\u00E1, J." . . "Gkalpakiotis, Spyridon" . "RIV/00216208:11120/07:00001457" . "9"^^ . . "Kvantitativn\u00ED stanoven\u00ED cirkuluj\u00EDc\u00EDch melanomov\u00FDch bun\u011Bk k v\u010Dasn\u00E9 detekci progrese onemocn\u011Bn\u00ED"@cs . "malignant melanoma; tumor markers; real-time RT-PCR"@en . . "\u010Cesko-slovensk\u00E1 dermatologie" . "Kvantitativn\u00ED stanoven\u00ED cirkuluj\u00EDc\u00EDch melanomov\u00FDch bun\u011Bk k v\u010Dasn\u00E9 detekci progrese onemocn\u011Bn\u00ED"@cs . "0009-0514" . "3" . "82" . . "Detection of melanoma cells in the peripheral blood is a promising method in monitoring of haematogenic tumor cell dissemination and thus in early detection of metastases. The opinion on a clinical relevance of the method is not uniform. Authors describe multimarker real-time PCR they successfully established for this purpose. Five melanoma cells markers were quantitatively analyzed from the peripheral blood: Melan-A/MART-1, gp 100, MAGE-3, MIA and tyrosinase. During prospective study 65 patients after high risk skin melanoma excision were screened. Staging and blood sample analyses for circulating cells were performed every three months during 15 months period. In 18 patients progression was noted during the study. All of them showed statistically significant elevation of tumor markers 0 to 9 months from disease progression. MAGE-3 was the most sensitive marker. In patients with disease progression three markers neerytrocywere positive in 39%, one marker in 33% and two markers in 28%. Quantitative de"@en . "Arenbergerov\u00E1, Monika" . . "Stuchl\u00EDk, D." . . "Arenberger, Petr" . . "Kvantitativn\u00ED stanoven\u00ED cirkuluj\u00EDc\u00EDch melanomov\u00FDch bun\u011Bk k v\u010Dasn\u00E9 detekci progrese onemocn\u011Bn\u00ED" . "Jandov\u00E1, E." . "CZ - \u010Cesk\u00E1 republika" . . .